Chimeric Therapeutics ASX: CHM

Our Quarterly Activities Report for the period ending 30 September 2026 has been released.
View the full $CHM report here: app.sharelinktechnologies.com/announcement-p…

We've ceased enrolment & dosing in the $CHM CDH17 Phase 1 study following a second dose-limiting toxicity at Dose Level 3. Anti-tumour activity observed supports CDH17 as a valid target for further development, with a focus on an in vivo approach.
app.sharelinktechnologies.com/announcement-p…

Our CEO, Rebecca McQualter, presented at last week’s TechKnow Invest Roadshow held in Melbourne & Sydney. A recording of the presentation is now available.

View Rebecca’s presentation here: tinyurl.com/nhc48m3w

#CHM #Biotech #CellTherapy #ClinicalTrials #TechKnow2026 #ASX

Our Quarterly Activities Report for the period ending 30 June 2026 has been released.

View the full $CHM report: app.sharelinktechnologies.com/announcement-p…

We've received $1.62M advance on our FY2026 R&D tax incentive. The funding will support our ongoing Phase 1/2 clinical trial activities and general working capital as we continue our previously announced Strategic Review.
app.sharelinktechnologies.com/announcement-p…